09.01.2015 Views

Hormones And Mood In PMDD And Pregnancy - Faina Novosolov, MD

Hormones And Mood In PMDD And Pregnancy - Faina Novosolov, MD

Hormones And Mood In PMDD And Pregnancy - Faina Novosolov, MD

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>Hormones</strong> and <strong>Mood</strong><br />

in <strong>P<strong>MD</strong>D</strong> and<br />

<strong>Pregnancy</strong><br />

<strong>Faina</strong> <strong>Novosolov</strong>, M.D.<br />

Women’s <strong>Mood</strong> and Hormone Clinic<br />

UCSF/ LPPI<br />

415-771-7711 www.fainamd.com<br />

No other financial disclosures.


Educational Objectives<br />

• Diagnosis/treatment of <strong>P<strong>MD</strong>D</strong> vs PMS<br />

vs PME<br />

• Better understanding of the menstrual<br />

cycle in relation to mood symptoms<br />

• Understanding the second mechanism<br />

of SSRI’s<br />

• How to treat depression in pregnancy<br />

and risk factors to review with women<br />

during pregnancy/delivery


Menstrual Cycle<br />

Estrogen / E2 <br />

Testosterone <br />

Follicular <br />

Phase <br />

Luteal <br />

Phase


Brain Variability Controlled by<br />

Ovarian <strong>Hormones</strong><br />

Depending on where a woman is in her cycle,<br />

there is variability in the following:<br />

• <strong>Mood</strong><br />

• Verbal performance<br />

• Sexual interest<br />

• Visual-spatial performance<br />

-Sherwin, “Estrogenic effects on memory in women.” Ann N Y Acad Sci., Nov 1994 <br />

-Goldstein et al., “Sex Differences in Stress Response Circuitry Activation Dependent on Female Hormonal Cycle.” J<br />

Neurosci. 2010 January 13. <br />

-L. Brizendine, The Female Brain, 2006


Menstrual Cycle<br />

<strong>Mood</strong>/verbal <br />

Highest<br />

Sex Drive <br />

Visual-spatial


Best <br />

Worst <br />

week 1 2 3 4 <br />

-Stanicić A et al., “Psychophysical characteristics of the premenstrual period.” Coll Antropol. 2010 Dec;34(4):1421-5.


<strong>P<strong>MD</strong>D</strong> vs Normal PMS<br />

Normal PMS (Premenstrual Syndrome):<br />

• 80% of women<br />

• Mild to moderate emotional fluctuations<br />

<strong>P<strong>MD</strong>D</strong> (Premenstrual Dysphoric Disorder):<br />

• 8-10% of women<br />

• Severe moods swings, depressed mood,<br />

irritability, or anxiety and 4 other symptoms<br />

(occurring exclusively during the luteal phase<br />

(weeks 3-4) and remitting within a few days of the<br />

onset of menses


DSM-IV Research Criteria For <strong>P<strong>MD</strong>D</strong><br />

-It is considered “Depression NOS”<br />

A. <strong>In</strong> most menstrual cycles during the past year, five (or more) of the following symptoms<br />

were present for most of the time during the last week of the luteal phase, began to remit<br />

within a few days after the onset of the follicular phase, and were absent in the week<br />

postmenses, with at least one of the symptoms being either (1), (2), (3), or (4):<br />

1. Markedly depressed mood, feelings of hopelessness, or self-deprecating thoughts<br />

2. Marked anxiety, tension, feelings of being "keyed up" or "on edge"<br />

3. Marked affective lability (e.g., feeling suddenly sad or tearful )<br />

4. Persistent and marked anger or irritability or increased interpersonal conflicts<br />

5. Decreased interest in usual activities (e.g., work, school, friends, hobbies)<br />

6. Subjective sense of difficulty in concentrating<br />

7. Lethargy, easy fatigability, or marked lack of energy<br />

8. Marked change in appetite, overeating, or specific food cravings<br />

9. Hypersomnia or insomnia<br />

10. A subjective sense of being overwhelmed or out of control<br />

11. Other physical symptoms, such as breast tenderness or swelling, headaches, joint or<br />

muscle pain, a sensation of "bloating," or weight gain<br />

B. The disturbance markedly interferes with work or school or with usual social activities and<br />

relationships with others<br />

C. The disturbance is not merely an exacerbation of the symptoms of another disorder<br />

(although it may be superimposed on any of these disorders).<br />

D. Criteria A, B, and C must be confirmed by prospective daily ratings during at least two<br />

consecutive symptomatic cycles.


Daily Record of Symptoms


Menstrual Cycle Week and<br />

All Psychiatric Admissions<br />

• If random,<br />

admissions of<br />

women to<br />

psychiatric hospitals<br />

for all psychiatric<br />

diagnoses would be<br />

25% on each week<br />

of the menstrual<br />

cycle<br />

70<br />

60<br />

50<br />

40<br />

30<br />

20<br />

10<br />

0<br />

1st 2nd 3rd 4th<br />

Week of Menstrual Cycle <br />

Hospital<br />

Admits<br />

-Luggin et al. “Acute psychiatric admission related to the menstrual cycle.” Acta Psychiatrica Scandinavica, Vol 69, Issue 6, pp 461–465,<br />

June 1984. <br />

-Targum et al. “Menstrual cycle phase and psychiatric admissions.” , J Affect Disord. 22(1-2):49-53, May-Jun 1991.


Menstrual Cycle<br />

Estrogen / E2 <br />

Progesterone <br />

Testosterone <br />

Follicular <br />

Phase <br />

Luteal <br />

Phase


<strong>P<strong>MD</strong>D</strong><br />

Progesterone → Allopregnanolone (ALLO)<br />

soothing, like Valium<br />

• ALLO= a neuroactive metabolite of progesterone<br />

and works on GABA (gamma-aminobutyric acid)<br />

receptors in the brain<br />

• Hence, ALLO is a powerful anxiolytic,<br />

anticonvulsant, and anesthetic agent which<br />

decreases anxiety and depression.<br />

• Barbituates, benzodiazepines and alcohol also<br />

work at this receptor<br />

-Lisa Griffin, 1999


<strong>P<strong>MD</strong>D</strong><br />

Progesterone → Allopregnanolone (ALLO)<br />

soothing, like Valium<br />

-Prozac, Paxil and Zoloft were found not only to increase<br />

Serotonin, but also to increase ALLO production by<br />

activating the enzyme that converts progesterone to ALLO<br />

(by decreasing the enzyme’s K m 10- to 30-fold)<br />

-Imipramine (Tofranil) had no effect on ALLO production<br />

-Works almost immediately<br />

Journal:<br />

-Lisa Griffin, <strong>MD</strong>, PhD and Synthia Mellon, PhD.<br />

Selective serotonin reuptake inhibitors directly alter activity of<br />

neurosteroidogenic enzymes.<br />

Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13512-7.


2 Main Treatments<br />

• SSRI’s:<br />

<strong>P<strong>MD</strong>D</strong><br />

– Either 7-10 days before menses to help boost ALLO, or<br />

daily if also depressed<br />

– Or, you can increase SSRI dose in luteal phase<br />

• <strong>Hormones</strong>:<br />

– Start an OCP, or change to one with a progesterone<br />

good for mood<br />

– Take OCP continuously<br />

• Women are sensitive to hormones in different ways – some to<br />

the hormone fluctuation, some to the amount, and some to the<br />

progestin type


All Possible <strong>P<strong>MD</strong>D</strong> Treatments<br />

Antidepressants<br />

-SSRI*<br />

-SNRI*<br />

-Clomipramine**<br />

Ovulation Suppression<br />

-OCP’s*<br />

-GnRH Agonists (Lupron)**<br />

-Danazol (inhibits LH/FSH)<br />

-Oophorectomy <br />

Anxiolytics<br />

-BZD**<br />

-Buspar**<br />

Other<br />

-Exercise<br />

-Calcium**<br />

-CBT*<br />

-Vit B6<br />

-NSAIDS<br />

-Diet<br />

-Chasteberry<br />

(may reduce FSH or Prolactin)<br />

*Efficacy in double-blind studies of <strong>P<strong>MD</strong>D</strong><br />

**Efficacy in double-blind studies of PMS<br />

-Teri Pearlstein, M.D. Warren Alpert Medical School of Brown University, APA Conference 2008


Advantages of SSRI’s<br />

• Fluoxetine, Sertraline and Paroxetine CR are FDA<br />

approved for <strong>P<strong>MD</strong>D</strong><br />

• Both continuous and intermittent dosing effective<br />

• <strong>In</strong>termittent Fluoxetine is effective for mood symptoms<br />

at both 10 and 20 mg. 20 mg is more effective for<br />

physical symptoms than 10 mg.*<br />

• No discontinuation symptoms with intermittent dosing<br />

• Dosing strategies can be tailored to a woman’s<br />

preferences<br />

*Cohen LS, et al. Obstet Gynecol. 2002; 100: 435-444.<br />

-Teri Pearlstein, M.D. Warren Alpert Medical School of Brown University, APA Conference 2008


<strong>In</strong>termittent Fluoxetine in <strong>P<strong>MD</strong>D</strong><br />

0<br />

-2<br />

DRSP <strong>Mood</strong><br />

Cluster<br />

DRSP Physical<br />

Cluster<br />

DRSP Social<br />

<strong>And</strong> Functional<br />

Impairment Cluster<br />

Mean change<br />

from<br />

baseline<br />

-4<br />

-6<br />

-8<br />

-10<br />

-12<br />

-14<br />

-16<br />

Placebo<br />

Fluoxetine 10 mg<br />

Fluoxetine 20 mg<br />

DRSP = Daily Record of Severity of Problems<br />

Cohen LS, et al. Obstet Gynecol. 2002; 100: 435-444.


Concerns With SSRI’s<br />

• Potential long-term effects: weight gain, sexual SEs<br />

• Lower doses are less effective for physical<br />

symptoms than for mood/ anxiety symptoms<br />

• Tolerance to dose over time<br />

• Symptom recurrence after dose discontinuation<br />

• <strong>Pregnancy</strong> during treatment (may not want to<br />

choose Paroxetine CR if pregnancy is a possibility)<br />

-Teri Pearlstein, M.D. Warren Alpert Medical School of Brown University, APA Conference 2008<br />

-Cohen LS, et al.” Obstet Gynecol. 2002; 100: 435-444.


Other Luteal Phase Treatments<br />

• Alprazolam up to 0.25 mg tid prn (taper at<br />

menses), or Ativan 0.5 mg prn<br />

• Spironolactone 50 mg bid for edema<br />

• Bromocriptine 2.5 mg for breast pain/<br />

tenderness (mastalgia)<br />

• NSAIDS for cramps/ leg pain<br />

-Teri Pearlstein, M.D. Warren Alpert Medical School of Brown University, APA<br />

Conference 2008


Which birth control pill is good for mood<br />

• Lower progestin potency:<br />

Ortho Evra patch <br />

Ovcon 35 <br />

Ortho-TriCyclen <br />

Othro-Cyclen <br />

Brevicon <br />

Modicon <br />

Necon 1/35 <br />

Alesse <br />

Levlite <br />

Tri-Levlen <br />

Triphasil <br />

Trivora <br />

-Rohr, UD. “The impact of testosterone imbalance on depression and women's health.” Maturitas. 2002 Apr 15;41<br />

Suppl 1:S25-46. <br />

-Jelovsek, FR. (2003). “Accurate Answers to Questions About Birth Control Pills. “ [e-book].


Which OCP is good for mood<br />

• Women are sensitive to hormones in different<br />

ways – some to the progestin, some to the<br />

amount and some to the hormonal fluctuation<br />

• Seasonale or any monophasic OCP taken<br />

continuously can stabilize mood<br />

• Women who are sensitive to hormonal<br />

fluctuation should avoid triphasic OCP’s<br />

• It takes about 2 cycles to see if a certain OCP<br />

will work


YAZ®<br />

• Contains:<br />

– Drospirenone 3 mg<br />

– Ethinyl estradiol 20 µg (Yasmine has 30 µg)<br />

• Shortened hormone-free interval:<br />

– 24 active pills, 4 inactive pills (Yasmine has 21<br />

active/ 7 inactive pills)<br />

• Efficacy was expected for physical symptoms.<br />

But, surprisingly, efficacy in mood and irritability<br />

was also seen with YAZ<br />

-Yonkers KA, Brown C, Pearlstein TB, et al. “Efficacy of a new low-dose oral contraceptive with<br />

drospirenone in premenstrual dysphoric disorder.” Obstet Gynecol. 2005;106:492-501.


Drospirenone<br />

• Derived from 17 alpha spirolactone<br />

• Analogue of spironolactone<br />

• Has antimineralocorticoid activity (leads<br />

to water diuresis)<br />

• <strong>In</strong>creases K+ retention, Na+ and water<br />

excretion<br />

• Has antiandrogenic activity


All OCPs (with estrogen)<br />

Can Lower Libido<br />

• The oral estrogen in OCPs increases SHBG (Sex<br />

Hormone Binding Globulin)<br />

• <strong>In</strong>creased SHBG → lower free testosterone<br />

• Oral estrogen and thyroid increase SHBG<br />

– Oral estrogen passes through the liver (vs<br />

some patches or endogenous estrogen) and<br />

binds up SHBG, increasing production of<br />

SHBG. Progesterone is bound by transcortin.<br />

-Rosner W. “Plasma steroid-binding proteins.” Endocrinology and Metabolism Clinics of North Am [1991, 20(4):697-720]. <br />

-Goodman MP. “Are all estrogens created equal A review of oral vs. transdermal therapy.” J Wom Health (Larchmt). 2012 Feb;21(2):161-9. Epub 2011 Oct 19. <br />

-Pakarinen P et al. “The effect of intrauterine and oral levonorgestrel administration on serum concentrations of SHBG, insulin and insulin-like growth factor<br />

binding protein-1.” Acta Obstet Gynecol Scand. 1999 May;78(5):423-8.


<strong>P<strong>MD</strong>D</strong> <strong>In</strong> Summary<br />

• <strong>P<strong>MD</strong>D</strong>: 8-10% of women<br />

• The current hypothesis: women who<br />

experience <strong>P<strong>MD</strong>D</strong> are sensitive to the change<br />

in estrogen and progesterone<br />

• SSRIs are effective treatments with daily or<br />

luteal phase dosing—higher doses are more<br />

effective for physical symptoms<br />

• YAZ® has similar efficacy to SSRI’s, both for<br />

physical and mood symptoms<br />

• The big question: should women with <strong>P<strong>MD</strong>D</strong><br />

be treated with OCP’s or SSRI’s first


Disorders with<br />

Premenstrual Exacerbation<br />

(PME)<br />

• Affective disorders<br />

• Anxiety disorders<br />

• Psychotic disorders<br />

• Eating disorders<br />

• Substance abuse<br />

• Migraine<br />

• Allergies<br />

• Asthma<br />

• Seizures<br />

• Personality<br />

disorders


Sample Question:<br />

Premenstrual dysphoric disorder (<strong>P<strong>MD</strong>D</strong>):<br />

A. is associated with hormonally abnormal<br />

menstrual cycles<br />

B. is associated with abnormal levels of hormones<br />

C. is associated with changing levels of sex steroids<br />

that accompany ovulatory menstrual cycles<br />

D. is seen in approximately 50% of women<br />

E. is not treated with SSRI’s<br />

F. all of the above


Sample Question:<br />

Premenstrual dysphoric disorder (<strong>P<strong>MD</strong>D</strong>):<br />

A. is associated with hormonally abnormal<br />

menstrual cycles<br />

B. is associated with abnormal levels of hormones<br />

C. is associated with changing levels of sex steroids<br />

that accompany ovulatory menstrual cycles<br />

D. is seen in approximately 50% of women<br />

E. is not treated with SSRI’s<br />

F. all of the above


Sample Case: “Help my <strong>P<strong>MD</strong>D</strong>”<br />

• 27 y/o married woman<br />

• “I have a serious case of<br />

<strong>P<strong>MD</strong>D</strong>. I get low energy,<br />

irritable and depressed. I start<br />

fights with my husband and<br />

often have to skip work. Then,<br />

when my period comes, I feel<br />

fine.”<br />

• “I have been using YAZ OCP<br />

and Effexor XR. It kinda helps,<br />

but not 100%.”


Things to Consider<br />

• PMS charting<br />

• Check labs: TSH, cbc to r/o anemia<br />

• Meds: educate about SSRIs being 1 st<br />

choice for <strong>P<strong>MD</strong>D</strong> (and safety in<br />

pregnancy since she’s a young, married<br />

woman)<br />

• Effexor not ideal: SSRIs are 1 st line<br />

(though some data that Effexor and<br />

Clomipramine also help with <strong>P<strong>MD</strong>D</strong>)<br />

• Since Effexor not working great<br />

anyway, consider Zoloft 25 mg or<br />

Prozac 10 mg<br />

• Discuss her future plans for pregnancy<br />

• Therapy


Things to Consider<br />

• Ask about libido: She’s on YAZ, which<br />

can lower her libido (via 2 mechanisms!!!)<br />

• If unsure, you can also check libido labs:<br />

– Free and total testosterone<br />

– SHBG<br />

– TSH<br />

– Prolactin<br />

– DHEA-S<br />

• May want to switch to another OCP or the<br />

Mirena or Copper IUD.


The Mommy Brain:<br />

<strong>Hormones</strong>, <strong>Pregnancy</strong> and <strong>Mood</strong><br />

• The smell of a newborn baby stimulates the<br />

woman to produce oxytocin – a love potion<br />

creating baby lust<br />

– Oxytocin is also released when talking to friends,<br />

or creating a connection<br />

– “A feel good” hormone – released in bonding and<br />

during orgasm<br />

• Throughout pregnancy, a woman is<br />

marinated in neurohormones manufactured<br />

by the fetus and placenta<br />

-L. Brizendine, The Female Brain, 2006


The Mommy Brain:<br />

<strong>Hormones</strong>, <strong>Pregnancy</strong> and <strong>Mood</strong><br />

• Progesterone: Spikes from 10-100x normal!<br />

• Thirst and hunger centers on full blast<br />

• Women become sensitive to smells,<br />

especially of foods—to avoid eating<br />

something that could harm the fragile fetus<br />

-L. Brizendine, The Female Brain, 2006


The Mommy Brain:<br />

<strong>Hormones</strong>, <strong>Pregnancy</strong> and <strong>Mood</strong><br />

• The size and structure of a woman’s brain change<br />

• Between 6 months to the end of pregnancy, fMRI<br />

scans show that her brain is shrinking!<br />

– Restructuring and building new maternal circuits<br />

• This state gradually returns to normal 6 months<br />

after giving birth<br />

-Oatridge et al. “Change in brain size during and after pregnancy: study in healthy women and women with<br />

preeclampsia.” AJNR Am J Neuroradiol. 2002 Jan;23(1):19-26.


Depression and <strong>Pregnancy</strong><br />

• 1-2 out of every every 10 pregnant women<br />

have symptoms of major depression<br />

• Women who have been depressed before are<br />

at higher risk<br />

• Range of treatments:<br />

– Support groups, light therapy, medications and ECT<br />

– <strong>In</strong>dividual therapy is highly recommended<br />

-Dobie SA, Walker EA. “Depression after childbirth.” J Am Board Fam Pract. 1992 May-Jun;5(3):<br />

303-11.


Depression and <strong>Pregnancy</strong><br />

• Depression carries serious risks:<br />

– poor nutrition<br />

– poor self-care<br />

– substance abuse<br />

– SI<br />

• Can lead to premature birth, low birth weight<br />

and developmental problems<br />

• Depressed mothers are often less able to care<br />

for themselves and/ or their children, or to bond<br />

with their children


What are the symptoms of PPD<br />

• <strong>MD</strong>E symptoms 1 month to 1 year<br />

postpartum<br />

• Things other than depression can<br />

cause some of these symptoms<br />

– Changes in appetite and trouble sleeping are<br />

common in pregnancy<br />

– Medical conditions, such as anemia and<br />

hypothyroidism, can cause low energy


Depression and <strong>Pregnancy</strong><br />

• What I tell women: the risks….<br />

– During pregnancy<br />

– During delivery<br />

– After delivery


During <strong>Pregnancy</strong><br />

• 2006 study—pregnant women with <strong>MD</strong>D are very<br />

likely to become ill again if they stop taking their<br />

medication<br />

• Many studies have found no link between<br />

antidepressants and serious malformations in<br />

newborns<br />

• 2005—FDA issued a warning about Paxil: taking<br />

the drug during the first three months of<br />

pregnancy may increase the risk of birth defects,<br />

particularly heart defects<br />

-Lee S. Cohen et al. “Relapse of Major Depression During <strong>Pregnancy</strong> in Women Who Maintain or Discontinue<br />

Antidepressant Treatment.” JAMA. 2006;295(5):499-507. <br />

-Levinson-Castiel R et al. “Neonatal abstinence syndrome after in utero exposure to SSRIs in term infants.”<br />

Arch Pediatr Adolesc Med. 2006 Feb;160(2):173-6.


During <strong>Pregnancy</strong><br />

• SSRI’s have been linked to small increased risks of:<br />

– heart defects (0.9% for 1 SSRI, 2.1% >1 SSRI, vs 0.5%)<br />

– hydronephronsis (kidney defects)<br />

– cleft palate (5% vs 2-4%)<br />

• 2012 study—found<br />

– Untreated maternal depression was associated with<br />

slower rates of fetal body and head growth<br />

– Fetuses from mothers treated with SSRIs had no delay<br />

in body growth but did have delayed head growth and<br />

were at increased risk for preterm birth<br />

-Pedersen LH et al. “SSRIs in pregnancy and congenital malformations: population based cohort study.” BMJ. 2009 Sep 23;339:b3569.<br />

doi: 10.1136/bmj.b3569. <br />

-El Marroun H et al. “Maternal Use of SSRIs, Fetal Growth, and Risk of Adverse Birth Outcomes.” Arch Gen Psychiatry. 2012 Mar 5.<br />

[Epub ahead of print]


During <strong>Pregnancy</strong>: Autism Risk<br />

• 2011 study—examined fetal SSRI exposure in 298<br />

children with autism spectrum disorders (ASDs) and<br />

1507 control children<br />

• Possible association between SSRI exposure and<br />

childhood ASD<br />

• Things to consider<br />

– Rx use not confirmed<br />

– dx from records not interview<br />

– factors not controlled for (tobacco, alcohol, drug use)<br />

– mothers of ASD kids were much older<br />

– need to distinguish role of meds vs underlying dz<br />

-Croen LA et al. “Antidepressant use during pregnancy and childhood autism spectrum disorders.” Arch Gen Psychiatry.<br />

2011 Nov;68(11):1104-12. doi: 10.1001/archgenpsychiatry.2011.73. Epub 2011 Jul 4.


During <strong>Pregnancy</strong> (cont)<br />

• "Clinicians and patients need to balance the small risks<br />

associated with SSRIs against those associated with<br />

undertreatment or no treatment.”<br />

-Sept 2009, Pederson et al., British Medical Journal (BMJ)<br />

• Although relative risks for certain anomalies are elevated<br />

with SSRI use, absolute risks are low. For example,<br />

excess risk for a major cardiovascular anomaly<br />

attributable to SSRI use is 37 additional cases per<br />

10,000 women.<br />

-July 2011, Malm et al., Obstetrics and Gynecology


During Delivery<br />

Neonatal Abstinence Syndrome (NAS):<br />

– Baby “withdrawal” from SSRIs<br />

• breathing or feeding problems, jerky movements, seizures,<br />

irritability, abnormal crying, tremor<br />

• Sx usually subside from 48 hours to a few days<br />

Persistent Pulmonary Hypertension of the Newborn (PPHN):<br />

– 2006 study—babies exposed to SSRIs in late pregnancy (after 20<br />

weeks) may be more likely to have PPHN<br />

– Since then, we have 7 studies total: 3 showed no link between PPHN<br />

and SSRI’s, the other 4 showed some increased risk<br />

– FDA will update their SSRI drug label to reflect the conflicting results<br />

– Key point: Factors associated with depression itself (vs. SSRI<br />

exposure) can increase PPHN risk (obesity, smoking, premature birth,<br />

cesarean section)<br />

-Chambers CD et al. “SSRIsand risk of persistent pulmonary hypertension of the newborn”. New Engl J Med 2006; 354(6):579-87. <br />

-Ruta Nonacs. “SSRI’s and PPHN: the FDA revises its warning.” MGH Center for Women’s Health website, Jan 17, 2012. <br />

-Jordan AE et al. “SSRI use in pregnancy and the neonatal behavioral syndrome..” J Matern Fetal Neonatal Med. 2008 Oct;21(10):745-51.


During Delivery (cont)<br />

• Both untreated depression/ anxiety and SSRI<br />

exposure have been correlated with early or<br />

preterm birth<br />

• 2009 study—SSRI use in late pregnancy<br />

correlated with an elevated risk of gestational<br />

hypertension and preeclampsia in the mother<br />

-Catov JM et al. “Anxiety and optimism associated with gestational age at birth and fetal growth.” Matern Child Health J.<br />

2010 Sep;14(5):758-64. <br />

-Rita Suri et al. “Effects of Antenatal Depression and Antidepressant Treatment on Gestational Age at Birth and Risk of<br />

Preterm Birth.” The American Journal of Psychiatry. 2007 August ; 8(164):1206-1213. <br />

-Li, D. Liu L., Odouli R. “Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a<br />

prospective cohort study.” Human Reproduction 2008 Oct 23 (E-published ahead of print). <br />

-Toh et al. “SSRI use and risk of gestational hypertension.” Am J Psychiatry. 2009 Mar;166(3):320-8. Epub 2009 Jan 2.


After Delivery<br />

• No link to serious problems with language,<br />

behavior or intelligence<br />

• There has been no data reported on long<br />

term effects of antidepressants on the baby’s<br />

well being<br />

-<br />

Nulman I, et al. “Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetals<br />

life: a prospective, controlled study.” Am J Psychiatry 2002; 159: 1889-1895. <br />

-Nulman I, et al. “Neurodevelopment of children exposed to antidepressant and antipsychotic medications during<br />

pregnancy.” <strong>In</strong> Clinics in Developmental Med No. 188. London, Mac Kieth Press, 2011.


Choosing an Antidepressant<br />

• We don't know all the answers. No drug is entirely safe. A<br />

woman and her health care team must look at her case and<br />

carefully weigh risks/ benefits of:<br />

– The drug<br />

– Other treatments<br />

– The risk of untreated depression<br />

• If a woman has been or is currently stable on a certain<br />

SSRI, that medication is usually continued (unless it is<br />

Paxil, which is generally contraindicated)<br />

• Zoloft and Prozac are often chosen b/c Zoloft has the<br />

lowest levels in breast milk and Prozac’s long half-life


Important Points<br />

• Pt should be followed closely by psychiatrist and ob/gyn<br />

• Prenatal vitamins and folic acid<br />

• Check thyroid, CBC and other lab work<br />

• Deliver the baby in a hospital to adequately monitor and<br />

assess any possible delivery complications<br />

• Stress reduction techniques and individual therapy<br />

• Be on the lowest number of meds and the lowest dose<br />

necessary<br />

• Start low and go slow


Within the first month after giving<br />

birth: 10% of women will have had<br />

‘Postpartum Depression’<br />

• Huge ‘crash’ in hormones after<br />

pregnancy<br />

• Postpartum: the brain and ovaries<br />

experience the re-establishment of<br />

menstrual cycle hormone pulses just as<br />

during the onset of puberty


Psychiatric Admissions in 2 Years<br />

70<br />

Before and After Delivery<br />

Admissions/month*<br />

60<br />

50<br />

40<br />

30<br />

20<br />

10<br />

<strong>Pregnancy</strong><br />

0<br />

–2 Years – 1 Year Childbirth +1 Year +2 Years<br />

*Rate of psychiatric admissions in the 2 years before and after delivery in a population of<br />

470,000 people with 54,087 births in a 12-year period<br />

Kendell RE, et al. Br J Psychiatry. 1987;150:662.


Postpartum Depression<br />

• Postpartum Depression:<br />

– Technically, onset is within 4 weeks after childbirth, but<br />

can be seen up to 1 yr later (in DSM, it’s a specifier:<br />

“With Postpartum Onset”)<br />

– 10-15% of women will experience postpartum depression<br />

within the 1 st month after giving birth<br />

• ‘Baby blues’:<br />

– Affect up to 80% of women during the 10 days<br />

postpartum (usually lasts 2 weeks)<br />

– These are transient, do not impair function, and don’t<br />

meet <strong>MD</strong>D criteria


Sample Question:<br />

Which antidepressant is found to be<br />

transmitted in the lowest amounts in breast<br />

milk<br />

A. Prozac<br />

B. Celexa<br />

C. Zoloft<br />

D. Lexapro<br />

E. Klonopin


Sample Question:<br />

Which antidepressant is found to be<br />

transmitted in the lowest amounts in breast<br />

milk<br />

A. Prozac<br />

B. Celexa<br />

C. Zoloft<br />

D. Lexapro<br />

E. Klonopin


Sample Case: “I want to stop my meds”<br />

• 33-year-old married<br />

woman<br />

• Had a <strong>MD</strong>E 1 yr ago<br />

• She responded well to<br />

Zoloft 100 mg and has<br />

been symptom free for<br />

9 months.<br />

• She wants to stop her<br />

Zoloft so she can get<br />

pregnant.<br />

• What do you do


Consider a Trial off Meds If:<br />

• There was only one previous <strong>MD</strong>E<br />

• It occurred more than 9 months ago<br />

• It resolved quickly with medication<br />

• She has been functioning well for<br />

more than 6 months<br />

• No family history<br />

• No current stressors<br />

• Good financial and emotional<br />

supports<br />

• Good insight into her illness so she<br />

can recognize early signs<br />

• She is cooperative with treatment<br />

and willing to restart meds if needed<br />

• At it’s worst, there was no significant<br />

decompensation or SI


Educational Objectives<br />

• Diagnosis/treatment of <strong>P<strong>MD</strong>D</strong> vs PMS<br />

vs PME.<br />

• Better understanding of the menstrual<br />

cycle in relation to mood symptoms.<br />

• Understanding the second mechanism<br />

of SSRI’s.<br />

• How to treat depression in pregnancy<br />

and risk factors to review with women<br />

during pregnancy/delivery.


The End<br />

Thank You!<br />

A special thank you to Dr. Louann Brizendine

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!